Saijun Biotechnology

About Saijun Biotechnology

Guangzhou Saijun Biotechnology Co., Ltd. is a clinical-stage biotechnology company established in March 2016, specializing in the research and development of stem cell-based therapeutics. The company focuses on developing treatments for diseases that currently lack effective therapeutic options, as well as for emergency medical situations. The firm has constructed a 3,000 square meter facility with GMP-standard laboratories for its clinical translation platform, including areas for cell storage, quality inspection, and research.

Saijun Biotechnology was co-founded by a team that includes Professor Xiang-Fu a National Outstanding Young Scientist Fund winner, as a key leader in its research and development efforts. The management team includes Dr. Sunxing Yan, who holds a Ph.D. in stem cells and tissue engineering and serves as General Manager, and Dr. Yutian Shen, the CEO, who has a background in public policy and management for health care. The company has secured significant government funding, including over 8 million RMB in 2016 and 15 million RMB in 2018 from various provincial and municipal programs. It has also completed A-round financing, raising 15 million RMB.

The company's product pipeline is centered on mesenchymal stem cells (MSCs) and is structured in three stages. The first-generation product is a bone marrow mesenchymal stem cell injection aimed at emergency medical applications. This is followed by a second generation of targeted MSC products for precision treatment and a third generation of universal off-the-shelf stem cell products. Saijun's research and clinical trial pipeline addresses a range of conditions, including acute respiratory distress syndrome, acute-on-chronic liver failure, inflammatory bowel disease, and ischemic stroke. In a notable collaboration, the company partnered with the team of academician Nanshan Zhong at the First Affiliated Hospital of Guangzhou Medical University for a clinical research filing on using mesenchymal stem cells to treat severe COVID-19 pneumonia.